The objectives for the DMDG course on Pharmacokinetics in Drug Discovery are to develop an understanding and appreciation of the
importance and contribution of drug metabolism and pharmacokinetics to drug design by first intent. The course highlights the
importance of physicochemical properties in drug design and covers the fundamental aspects of pharmacokinetics and pharmacodynamics,
safety study design and toxicokinetics, the importance of ADME and the relevance of metabolite pharmacokinetics.
Approaches to the prediction of human pharmacokinetics and therapeutic dose are introduced. Concepts associated with the assessment
of pharmacokinetics in association with pharmacodynamic endpoints in First Time in Human and Proof of Mechanism and Concept clinical
trials are also discussed.
The overarching theme is one of data integration and the utility of pharmacokinetic evaluation to assess and contextualise risk vs
benefit at key stages of drug discovery and development. To illustrate the utility of DMPK science in the pharmaceutical industry in
relation to compound progression the delegates also have the opportunity to conduct a series of workshops and integrate data from
numerous sources to overcome real life problems and decisions in preclinical drug discovery and development.
To illustrate the utility of
DMPK science in the pharmaceutical industry in relation to compound
progression delegates also have the opportunity to participate in a series
of workshops and integrate data from numerous sources to overcome real life
problems and decisions faced by project teams in preclinical drug discovery
The course takes the format of a series of lectures detailing theory and practice where the content is reinforced by the conduct of
tutorials in small break out groups to create a forum for discussion and further learning. Students will be expected to play an
active role in data calculation, interpretation and discussion.